CoChat

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

Open access

The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.

Abstract

Dasatinib (BMS-354825), a novel dual SRC/BCR-ABL kinase inhibitor, exhibits greater potency than imatinib mesylate (IM) and inhibits the majority of kinase mutations in IM-resistant chronic myeloid leukemia (CML). We have previously demonstrated that IM reversibly blocks proliferation but does not induce apoptosis of primitive CML cells. Here, we have attempted to overcome this resistance with dasatinib. Primitive IM-resistant CML cells showed only single-copy BCR-ABL but expressed significantly higher BCR-ABL transcript levels and BCR-ABL protein compared with more mature CML cells (P = .031). In addition, CrKL phosphorylation was higher in the primitive CD34+CD38– than in the total CD34+ population (P = .002). In total CD34+ CML cells, IM inhibited phosphorylation of CrKL at 16 but not 72 hours, consistent with enrichment of an IM-resistant primitive population. CD34+CD38– CML cells proved resistant to IM-induced inhibition of CrKL phosphorylation and apoptosis, whereas dasatinib led to significant inhibition of CrKL phosphorylation. Kinase domain mutations were not detectable in either IM or dasatinib-resistant primitive CML cells. These data confirm that dasatinib is more effective than IM within the CML stem cell compartment; however, the most primitive quiescent CML cells appear to be inherently resistant to both drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2005-07-2947

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Research works printed but not linked: 2

  1. Clark RE, Knight K, Lucas CM, Pirmohamed M, Wang L. Expression of the imatinib drug transporters HOCT1 and MDR1 levels determines imatinib response and development of Bcr-Abl kinase mutations in chronic myeloid leukemia (CML). Exper Hematol.2005;33: 51-52.
  2. Jiang X, Zhao Y, Chan WY, et al. Bcr-Abl transcripts are present at the highest level in the most primitive lin–CD34+CD38– leukemic cells from CML patients with chronic phase disease and then progressively decrease as they differentiate [abstract]. Blood.2003;102: 418a.

Cited by

See all 651

Metadata

Authors
Copland, M., Hamilton, A., Elrick, L. J., Baird, J. W., Allan, E. K., Jordanides, N., Barow, M., Mountford, J. C., & Holyoake, T. L.
Affiliations
Glasgow Royal Infirmary (GB)
Venue
Blood
Published
2006-06-01
Volume
107
Issue
11
Pages
4532-4539
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2149468947
Cited by
635
References
63
Citations by year
2026: 4 · 2025: 9 · 2024: 6 · 2023: 13 · 2022: 12 · 2021: 13 · 2020: 18 · 2019: 20 · 2018: 15 · 2017: 33 · 2016: 37 · 2015: 22 · 2014: 32 · 2013: 56 · 2012: 49
FWCI
35.60
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Bristol-Myers Squibb
  • Novartis Pharma
  • Medical Research Council
Topics
  • Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
dasatinib, imatinib resistance, chronic myeloid leukemia, BCR-ABL tyrosine kinase, Src family kinases, CrkL phosphorylation, apoptosis, kinase domain mutations
MeSH terms
Imatinib Mesylate, Dasatinib, Benzamides, Humans, Nuclear Proteins, Phosphorylation, Piperazines, Pyrimidines, RNA, Neoplasm, Thiazoles, Neoplastic Stem Cells, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Gene Dosage, HL-60 Cells, Antigens, CD34, Drug Resistance, Neoplasm, K562 Cells, Adaptor Proteins, Signal Transducing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. https://app.cochat.ai/papers/10.1182/blood-2005-07-2947
The paper
Copland, M., Hamilton, A., Elrick, L. J., Baird, J. W., Allan, E. K., Jordanides, N., Barow, M., Mountford, J. C., & Holyoake, T. L. (2006). Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. https://doi.org/10.1182/blood-2005-07-2947

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.